NCR Voyix Corporation (VYX)
NYSE: VYX · Real-Time Price · USD
12.94
-0.68 (-4.99%)
At close: Aug 1, 2025, 4:00 PM
13.19
+0.25 (1.93%)
After-hours: Aug 1, 2025, 7:59 PM EDT
Theseus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts that cover Theseus Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $14.4, which forecasts a 11.28% increase in the stock price over the next year. The lowest target is $11 and the highest is $17.
Price Target: $14.40 (+11.28%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 9, 2025.
Analyst Ratings
The average analyst rating for Theseus Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 3 | 3 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stephens & Co. | Stephens & Co. | Buy Maintains $12 → $15 | Buy | Maintains | $12 → $15 | +15.92% | Jun 9, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $8.5 → $11 | Hold | Maintains | $8.5 → $11 | -14.99% | May 9, 2025 |
| Needham | Needham | Strong Buy Maintains $15 → $13 | Strong Buy | Maintains | $15 → $13 | +0.46% | May 9, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $13 → $11 | Hold | Maintains | $13 → $11 | -14.99% | Apr 2, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $17 | Buy | Reiterates | $17 | +31.38% | Mar 25, 2025 |
Financial Forecast
Revenue This Year
2.63B
from 2.83B
Decreased by -6.94%
Revenue Next Year
2.25B
from 2.63B
Decreased by -14.56%
EPS This Year
0.79
from 6.52
Decreased by -87.91%
EPS Next Year
0.98
from 0.79
Increased by 23.99%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 2.7B | 2.8B | 2.3B |
| Avg | 2.6B | 2.2B | 2.2B |
| Low | 2.5B | 2.1B | 2.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -2.8% | 4.9% | 0.2% |
| Avg | -6.9% | -14.6% | -3.6% |
| Low | -10.2% | -20.8% | -6.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.84 | 1.13 | 1.10 |
| Avg | 0.79 | 0.98 | 1.06 |
| Low | 0.75 | 0.82 | 1.03 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -87.1% | 43.9% | 12.9% |
| Avg | -87.9% | 24.0% | 8.6% |
| Low | -88.4% | 4.5% | 5.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.